Clinigen Group plc Stock

CLIN

GB00B89J2419

OTC Markets Traded

Latest news: Clinigen Group plc

06-16	Clinigen Limited Announces Appointment of Stephanie Jane Brooksbank to Director, Effective April 28, 2026	CI
04-10	Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
02-12	Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's Preemiefort Enteral Solution, Human Milk-Based Product in Japan	CI
01-28	Clinigen Limited Appoints Mr. Varun Sethi as Director, Effective January 22, 2026	CI
25-10-20	Clinigen Limited Announces Termination of Jerome Marie Joseph Charton as Director, Effective October 8, 2025	CI
25-09-29	Clinigen Limited entered into a definitive agreement to acquire SSI Strategy LLC from Amulet Capital Partners LP.	CI
25-03-24	Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2024	CI
25-01-26	Tepsivo Oy announced that it has received funding from Clinigen Limited	CI
24-12-17	Clinigen Limited acquired Ascenian Consulting and Market Research LLC.	CI
24-08-05	Clinigen Limited acquired Kinesys Consulting Limited.	CI
23-09-12	Clinigen Launches NaviGATE an Educational Programme for Rare Disease Patients and Organizations	CI
23-08-09	CNX Therapeutics Limited acquired Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol®, four cancer support therapies from Clinigen Limited.	CI
23-05-08	Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2022	CI

More news

Analysts' recommendations: Clinigen Group plc

20-11-25

Clinigen : JPMorgan Starts Clinigen Coverage with Neutral, Sets PT

More recommendations

Press Releases: Clinigen Group plc

23-03-28	JCR Pharmaceuticals implements IZCARGO Named Patient Supply Program	AQ
23-03-28	Clinigen : Supplier Code of Conduct 2023	PU
23-03-20	Adragos Pharma acquires Clinigen's development unit, Lamda Laboratories	AQ
23-03-20	Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories	AQ
23-03-10	Clinigen : Global Human Rights & Anti Slavery Policy	PU

More press releases

News in other languages: Clinigen Group plc

22-02-11	Humanigen lanceert managed access program (MAP) voor lenzilumab
22-02-10	Humanigen lance un Programme d’accès géré pour le lenzilumab
22-02-10	Humanigen startet verwaltetes Zugangsprogramm für Lenzilumab
22-02-10	Humanigen lancia il programma di accesso gestito per Lenzilumab
22-02-10	Humanigen lanza un programa de acceso gestionado para lenzilumab

More news

Managers and Directors: Clinigen Group plc

Manager	Title	Age	Since
Gregory Skalicky CEO	Chief Executive Officer	55	2026-07-19
Fernando Ballester DFI	Director of Finance/CFO	-	2024-07-31
Nicky Wisener PRN	Corporate Officer/Principal	-	2020-08-31

Director	Title	Age	Since
Richard John Paling BRD	Director/Board Member	56	2023-01-02
Paul Carter CHM	Chairman	66	2025-06-10

More insiders

Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

Employees

1,071

Sector

More about the company